Table 2.
Prevalence of hormonal medication use during menopause by participant and by visit, Women’s Interagency HIV Study, 2008–2020.
| Menopause before 41 N (%) | Menopause 41–45 N (%) | Menopause 46–50 N (%) | ||||
|---|---|---|---|---|---|---|
| Participanta (N=35) | Visits (N=255) | Participantb (N=101) | Visits (N=775) | Participantc (N=442) | Visits (N=1,548) | |
| Hormone use | ||||||
| Vaginal estrogend | 0 (0) | 0 (0) | 16 (16) | 134 (17) | 3 (1) | 25 (2) |
| Menopausal hormone therapye | 5 (14) | 10 (4) | 16 (16) | 49 (6) | 29 (7) | 57 (4) |
| Hormonal contraceptionf | 13 (37) | 37 (15) | 10 (10) | 34 (4) | 2 (0) | 2 (0) |
| Any oral hormonesg | 18 (51) | 47 (18) | 24 (24) | 82 (11) | 30 (7) | 59 (4) |
Median [interquartile range] of visits between premature menopause before age 41 and age 51 was 5 [2,9].
Median [interquartile range] of visits between premature menopause between ages 41 and 45 and age 51 was 5 [2,9].
Median [interquartile range] of visits between premature menopause between ages 46 and 50 and age 51 was 2 [1,4].
Self-reported use of prescription drug that was classified as vaginal estrogen.
Self-reported use of hormone therapy or self-reported use of prescription drug that was classified as hormonal therapy
Self-reported use of oral contraceptives, implants, Depo Provera, or hormonal IUDs or self-reported use of a prescription drug that was classified as hormonal contraception. 8
Includes hormone therapy and hormonal contraceptives.